



Media release – 20 April 2015

Clearbridge Biomedics and LIDE Biotech partner to set up a CRO Circulating Tumour Cell processing facility in China

- **The first circulating tumour cell (“CTC”) processing facility in China**
- **Facility leverages on Clearbridge Biomedics’ ClearCell® FX1 System, which provides label-free, non-invasive, real-time ‘liquid biopsy’**
- **Cancer cells retrieved from blood are intact and viable, opening up the potential for cell-based work and animal work as well as molecular analysis.**

20 April 2015, *Singapore and Shanghai* – Shanghai LIDE Biotech Co., LTD (LIDE), a China registered company that focuses on translational medicine services and Singapore-based Clearbridge Biomedics have established a new exclusive partnership for the Contracted Research Organisation (CRO) market in China. The two partners will jointly set up the LIDE-Clearbridge CRO CTC Hub to provide circulating tumour cell (CTC) processing services. This facility will be part of LIDE’s existing 18,298 sqft facility in Shanghai, and is already up and running. This is China’s first CTC processing facility.

The LIDE-Clearbridge CRO CTC Hub will target biotech and pharmaceutical companies, as well as hospitals, helping to accelerate their therapeutic and drug discovery research. In addition to CTC processing services, the facility provides complementary downstream analysis services, including cell enumeration, immunohistochemistry testing, fluorescence in situ hybridisation, cell culture, patient-derived tumour xenograft (PDX) for drug sensitivity testing and genomic profiling using next generation sequencing.


The Hub leverages upon the ClearCell® FX1 system, the award-winning, label-free, automated CTC isolation system. Developed by Clearbridge Biomedics, the ClearCell® FX is able to isolate intact and viable CTCs from a patient’s blood sample. CTCs are cells that have detached from the primary tumour and circulate in the patient’s bloodstream. They are extremely rare - a millilitre of blood contains a few CTCs mixed with billions of blood cells. CTCs play a significant role in metastasis of the cancer, as the ‘seeds’ for the spread and growth of new tumours.

“Most patients do not die from their primary tumour, but when the disease spreads to another organ. By better understanding how CTCs lead to the metastatic spread of this disease, we will be able to develop better ways to diagnose, treat and manage cancer,” said Johnson Chen, Managing Director and Founder Clearbridge Biomedics. “This partnership between Clearbridge Biomedics and LIDE comes at an opportune time, as it allows us to reach out to the growing drug development market in China. Through this new partnership, we are able to support the pharmaceutical industry, which has already demonstrated significant interest using to CTC technology to empower the development of new therapeutic solutions in the fight against cancer.”

“Clearbridge BioMedics’ unique CTC enrichment technology will enable us to provide new real-time insights to our pharma partners and customers,” said Dr. Wen Danyi, CEO of LIDE Biotech. “Combined with our powerful PDX capabilities and leading downstream analysis, we can now enable comprehensive studies into metastasis biology and cancer pathogenesis; that can contribute to personalized precision medicine and timely, tailored, treatments for cancer patients.”

In this partnership, Clearbridge Biomedics will be bringing technology and know-how as a leading “liquid biopsy” technology company in Asia. This will complement LIDE’s world-class capabilities in patient-derived xenografts, pre-clinical testing and development services. The LIDE-Clearbridge CRO CTC Hub’s integrated service solution will be a “one-stop-shop” for oncology research, therapeutic target development and biomarker validation for the cancer researcher, biotechs and pharmaceutical companies.

- End -



Photos (Left to Right): (1) Clearbridge BioMedics and Shanghai LIDE Biotech team members with the ClearCell® FX1 System at the LIDE-Clearbridge CRO CTC Processing Hub in Shanghai. (2) A laboratory technician performing CTC enrichment. (3) The ClearCell® FX System. (4) The CTChip® FR1

About Clearbridge BioMedics

Clearbridge BioMedics is an oncology research and diagnostics company that enables real-time liquid biopsy using a label-free CTC enrichment platform. It is a Singapore-MIT Alliance for Research and Technology (SMART) / National University of Singapore (NUS) spinoff company that is committed to developing medical devices, which will impact the world and revolutionize cancer diagnostics and patient care, by leveraging on ground-breaking technology from research partners.

The ClearCell® FX1 System comprises patented CTChips®, which are able to effectively detect, isolate and retrieve intact and viable CTCs from patient blood. The System uses inertial focusing microfluidics for label-free CTC enrichment, capturing heterogeneous and dynamic cancer cells that can be used for cancer screening, diagnosis, staging, personalised medicine and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America.

www.clearbridgebiomedics.com

<https://www.youtube.com/watch?v=aRBuOxLfX3g>

About Circulating Tumour Cells (“CTCs”)

Circulating Tumour Cells (“CTCs”) are extremely rare cells that have detached from solid tumours, travel in the peripheral bloodstream and can cause the cancer to spread. They are considered the seeds in metastasis and can be a clear indication of disease progression.

About LIDE

Specializing in personalized precision medicine, LIDE provides cutting edge capabilities in *in vivo* efficacy studies on patient-derived xenograft models (PDX), *in vitro* cells-based assays, tumor chemosensitivity assays on patient primary tumor cells and molecular diagnostics. In addition to providing in-depth knowledge in oncology research, LIDE is committed to one-stop-shop solution for biotech companies, pharmaceutical companies and patients. LIDE has extensive access to multiple human primary tumor types for experimental research, and the ability to take advantage of exciting technology recently developed such as *in vivo* anti-cancer drug testing with humanized mice and label free CTC enrichment.

www.lidebiotech.com

Media enquiries can be directed to:

Clearbridge BioMedics media contact

Chan Yiu Lin (Ms)

Greener Grass Communications

Mobile: (+65) 9765 5897

Email: media@clearbridgeaccelerator.com

LIDE media contact

LIDE Biotech Co., Ltd

Xiaoran Qin, PhD

Mobile: (+86)-186 1688 2892

Email: xiaoran.qin@lidebiotech.com